Others linked the discovery of the BCR-ABL fusion protein (Rowley, 1973) to CML leading to the development of Imatinib (Druker et al., 1996) and newer generation inhibitors. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.